News

It has previously been shown that adding the drug abiraterone to the standard hormone therapy just after diagnosis improves survival of people with prostate cancer that has spread to other parts of the body. New findings from the STAMPEDE trial have confirmed that use of abiraterone remains the best option without the addition of enzalutamide. These results from the STAMPEDE trial were published in Lancet Oncology in early May 2023. For more on this, please click on the following link to the MRCCTU news feed: Giving abiraterone at early stages helps people with advanced prostate cancer to live longer | MRC Clinical Trials Unit at UCL   ...